Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-121 in Advanced Small Cell Lung Cancer
NCT07864207Phase 2
Key facts
- Status
- Recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
- Sponsor
- IDP Discovery Pharma
- Drugs
- IDP-121
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label trial of IDP-121 in small cell lung cancer (SCLC) (2 arms), sponsored by IDP Discovery Pharma. Primary endpoints: Maximum Tolerated Dose at 1 year and Recommended Phase 2 Dose at 1 year. Started Jul 2026; status: recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
IDP-121 with Topotecan
IDP-121 in combination with topotecan in patients with relapsed SCLC with PFI < 3 months
IDP-121 with platinum-based chemotherapy
IDP-121 in combination with platinum-based chemotherapy in patients with relapsed SCLC and PFI >= 3 months
03
Who it enrols
Adults with advanced/extensive stage SCLC that progressed after 1st line platinum-based chemotherapy, ECOG <= 2, adequate organ function, no active CNS metastases, and no significant cardiovascular, liver, or infectious diseases.
04
Endpoints
Primary
Maximum Tolerated Dose
Recommended Phase 2 Dose
Beyond the preview
Go deeper on NCT07864207.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07864207.